Accelerated hippocampal atrophy rates in stable and progressive amnestic mild cognitive impairment

Pei-Ning Wang1, Hsiu-Chih Liu, Jiing-Feng Lirng

  • 1Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan. pnwang@vghtpe.gov.tw

Psychiatry Research
|February 17, 2009
PubMed

Insights

Accelerated hippocampal atrophy, a key indicator of brain shrinkage, may signal Alzheimer's disease progression in individuals with mild cognitive impairment (MCI). This finding is crucial for early diagnosis and intervention strategies.

Area of Science:

  • Neuroscience
  • Gerontology
  • Radiology

Background:

  • Smaller hippocampal volume is linked to Alzheimer's disease (AD) risk in mild cognitive impairment (MCI).
  • Limited research exists on cognitive and hippocampal volume decline rates in stable MCI.
  • The influence of apolipoprotein E (ApoE) on medial temporal structures and cognition changes in MCI is understudied.

Purpose of the Study:

  • To investigate the rates of cognitive decline and hippocampal volume changes in amnestic MCI.
  • To examine the impact of apolipoprotein E (ApoE) genotype on these decline rates.
  • To identify predictors of conversion from MCI to AD.

Main Methods:

  • Annual neuropsychological and MRI assessments were conducted on 58 amnestic MCI subjects and 20 controls.
  • Annual decline rates in cognition, hippocampal, and amygdalar volumes were calculated.
  • ApoE genotyping was performed, and logistic regression analyzed conversion predictors.

Main Results:

  • Nineteen (32.7%) MCI subjects converted to AD within an average follow-up of 22.5 months.
  • Annual hippocampal atrophy rate correlated with memory decline; ApoE varepsilon4 did not significantly affect change rates.
  • Progressive MCI (MCI-P) showed higher cognitive and hippocampal volume decline rates than stable MCI (MCI-S) and controls.
  • Higher rates of hippocampal atrophy and cognitive decline predicted conversion to AD.
  • MCI-S subjects exhibited accelerated hippocampal atrophy compared to controls, despite minimal cognitive decline.

Conclusions:

  • Accelerated hippocampal atrophy is a significant early indicator in MCI subjects, potentially predicting progression to Alzheimer's disease.
  • Tracking hippocampal volume decline offers valuable insights into MCI progression and AD conversion risk.
  • While ApoE varepsilon4 status did not influence rates in this cohort, hippocampal atrophy itself is a critical marker.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Amnesia01:13

Amnesia

Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
Role of Hippocampus in Memory01:19

Role of Hippocampus in Memory

The hippocampus, a critical brain structure, plays an essential role in memory processing, particularly in the formation and retrieval of memory. This small, seahorse-shaped region is located within the medial temporal lobe, with one hippocampus in each brain hemisphere. Experimental studies involving lesions in the hippocampi of rats have demonstrated significant impairments in tasks such as object recognition and maze navigation, indicating the hippocampus involvement in both recognition and...